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Nanoparticle-based experimental therapeutics are currently being
investigated in numerous human clinical trials. CALAA-01 is a tar-
geted, polymer-based nanoparticle containing small interfering
RNA (siRNA) and, to our knowledge, was the first RNA interfer-
ence (RNAi)–based, experimental therapeutic to be administered
to cancer patients. Here, we report the results from the initial
phase I clinical trial where 24 patients with different cancers were
treated with CALAA-01 and compare those results to data ob-
tained from multispecies animal studies to provide a detailed ex-
ample of translating this class of nanoparticles from animals to
humans. The pharmacokinetics of CALAA-01 in mice, rats, mon-
keys, and humans show fast elimination and reveal that the max-
imum concentration obtained in the blood after i.v. administration
correlates with body weight across all species. The safety profile of
CALAA-01 in animals is similarly obtained in humans except that
animal kidney toxicities are not observed in humans; this could be
due to the use of a predosing hydration protocol used in the clinic.
Taken in total, the animal models do appear to predict the behav-
ior of CALAA-01 in humans.
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Therapeutics that use RNA interference (RNAi) as theirmechanism of action offer opportunities for inhibiting vir-
tually any gene target. Several RNAi-based therapeutics have
been and are currently being investigated in human clinical trials
(1). To date, results from two clinical investigations with cancer
patients have been reported (2, 3). In 2008, a cyclodextrin
polymer-based nanoparticle formulation containing siRNA
(CALAA-01) entered the clinic and, to our knowledge, was
the first example of systemic administration of a cationic poly-
mer–siRNA nanoparticle therapeutic to humans (4). Addition-
ally, CALAA-01 is the first, to our knowledge, systemically
administered nanoparticle of any kind to show the presence of
nanoparticles localized in patient tumors in amounts that cor-
related with dose levels given to the patients and demonstrate
gene inhibition by RNAi (2). Given that this class of nanoparticle
shows potential to deliver siRNAs to extrahepatic tumors, future
clinical translations of this type of therapeutic agent will rely
upon answering questions pertaining to the toxicity and efficacy
of this type of multicomponent formulation. To this end, we
present data from the phase Ia/Ib clinical trial of CALAA-01 and
correlate the data from humans with preclinical studies across
several nonhuman species to answer key questions about the
clinical translation of CALAA-01.
CALAA-01 is a four-component system that is manufactured
as a two-vial formulation for clinical dosing (Fig. 1). Vial 1
contains a mixture of three delivery components: (i) a linear,
cationic cyclodextrin-based polymer (CDP), (ii) a hydrophilic
polymer [adamantane polyethylene glycol (AD-PEG)] used
to promote nanoparticle stability in biological fluids, and (iii)
a human transferrin protein (hTf)-targeting ligand (AD-PEG-
hTf) displayed on the exterior of the nanoparticle to engage Tf
receptors (hTfR) on the surface of the cancer cells. The hTfR is
known to be up-regulated in human tumor cells, including mel-
anoma (5, 6). Vial 2 contains (iv) siRNA designed to reduce
the expression of the M2 subunit of ribonucleotide reductase
(RRM2). RRM2 is an established anticancer target (7, 8), and
i.v. administration of CALAA-01 inhibits the growth of human
tumor xenografts in mice by inhibiting the expression of RRM2
(9) (SI Appendix, Fig. S1). Vials 1 and 2 are mixed at the bedside,
and the components self-assemble into ∼75-nm nanoparticles (10).
The formulated nanoparticles are administered intravenously and
are designed to target tumor tissue via the enhanced permeability
and retention effect (11, 12).
The nature and complexity of CALAA-01 raised a number of
questions during its clinical translation: Would delivery of un-
modified siRNA to patients result in severe immunostimulation?
Would the positively charged polymer component of CALAA-01
result in coagulopathic effects and kidney toxicity in patients?
Would the off-target deposition of CALAA-01 in the liver result
in hepatotoxicity? Would the pharmacokinetic/pharmacody-
namic properties scale across species (from animals to humans)
based on body mass or body-surface area? Would the toxicities
observed in the preclinical toxicity studies translate into toxicity
in patients? Here, we present data from both humans and ani-
mals to provide insights into answering these and other questions
of importance for translating nanotherapeutics of this class.
Significance
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Results from a human phase Ia/Ib clinical trial are presented
and correlated to preclinical animal data to provide an initial
assessment of how this class of experimental therapeutics is
translated from animals to humans.
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Results
Overview of Human Phase Ia/Ib Clinical Trial.Nineteen patients were
enrolled in the phase Ia clinical trial between May 2008 and
September 2010 (SI Appendix, Table S1). Dose escalation from
3 to 30 mg/m2 (dose is listed as the amount of siRNA) in 15
patients was carried out between May 2008 and May 2009 with no
observed dose-limiting toxic events (DLTs). Then there was an
approximately 1-y enrollment gap until September 2010. Upon
trial resumption, the subsequent two patients in the 30 mg/m2
cohort experienced DLTs. The final two patients in the phase Ia
trial were treated at the previously well-tolerated 24 mg/m2 dose
level; however, these doses were not well tolerated by either patient.
Consequently, the clinical protocol was amended into a phase
Ib to include an additional cohort with a modified dose schedule
that was predicated on the idea that initial exposure to CALAA-01
at lower dose levels may desensitize patients to the innate immune
response that might be responsible for the adverse events (SI
Appendix, Table S1). Patients were to receive a lower dose of
CALAA-01 for cycle 1 (18 mg/m2—well tolerated by patients
during phase Ia) which, if there were no safety concerns, would
be followed by higher doses (27 mg/m2) in subsequent cycles. This
strategy was designed to improve the tolerability of CALAA-01 to
patients while maintaining its potential efficacy. Five patients were
enrolled in phase Ib between September 2011 and July 2012.
Two patients in this cohort experienced DLTs, and a decision
was made to end the study.
CALAA-01 Clinical Trial Patient Demographics and Tumor Response.
Table 1 and SI Appendix, Tables S2–S4, summarize the patient
demographics. All clinical characteristics and demographics were
similar across cohorts and dose levels. Twenty-four patients re-
ceived at least one dose of CALAA-01. Mean duration on
treatment was 36.6 d (median 28.4 d). Mean number of cycles
completed was 1.8 (median of 2 cycles) (SI Appendix, Table S5).
The primary reason for discontinuation from the study was
progressive disease in seven (29%) patients as evidenced by in-
crease in tumor size (SI Appendix, Table S6). During the study,
19 (79%) patients had at least one posttreatment scan and were
considered evaluable for tumor response by RECIST v1.0. No
objective tumor responses were observed; the best response per
RECIST v1.0 criteria reported by the investigators was stable
disease (SD) for 4 mo, a change of prior course, in one mela-
noma patient treated at the highest dose level. The patient re-
ceived a total of six cycles of CALAA-01 at 30 mg/m2 before
discontinuing due to progressive disease.
Dose-Limiting Toxicities in the Clinic. In cycle 1, two patients in the
30-mg/m2 dose cohort experienced DLTs. One patient had
metastatic prostate adenocarcinoma to the lungs and paraaortic
lymph nodes and had previously received radiation therapy and
progressed on bicalutamide. This patient developed grade 3 is-
chemic colitis, grade 2 diarrhea, and grade 1 fever and was im-
mediately discontinued from the study. The second DLT
occurred in a patient with metastatic melanoma who had pre-
viously received radiation therapy and high-dose IFN. The pa-
tient developed grade 4 fatigue, grade 2 flu-like symptoms, grade
2 muscular spasm, and grade 1 nausea and was immediately
discontinued from the study. Both patients were hospitalized and
fully recovered after receiving concomitant medication.
In phase Ib, the protocol was amended to include an addi-
tional cohort with a modified dose schedule (18 mg/m2 in cycle 1
followed by 27 mg/m2 in subsequent cycles) to possibly reduce
the innate immune response, improve the tolerability, and ma-
intain the potential efficacy of the study drug. Two patients in
phase Ib experienced DLTs. One patient with undifferentiated
small-cell carcinoma of the cervix with metastasis to the lungs
experienced grade 3 hypersensitivity reactions after the third and
fourth doses of 18 mg/m2 in cycle 1, necessitating infusion ter-
mination during dose 4. Another patient with rectal adenocar-
cinoma with metastasis to the lungs, who previously received
radiation therapy and five systemic therapies, showed grade 3
fatigue during cycle 1, and dose was reduced to 15 mg/m2 on
cycle 2 to minimize adverse events (AEs). Only two of the five
patients enrolled in phase Ib completed cycle 1 and progressed
to the 27-mg/m2 dose level.
Overall Safety Profile. All AEs are summarized in SI Appendix,
Table S7. The most common treatment-related AEs of any
grade with incidence in greater than 15% of patients were fatigue
(n = 12), chills (n = 12), and fever (n = 10). Grade 3/4-related
AEs occurring in multiple patients included lymphopenia (n = 3)
and fatigue (n = 2). Grade 3/4-related AEs during CALAA-01
infusions included hypersensitivity, ischemic colitis, diarrhea, and
fever (n = 1 each). Another treatment-related grade 3 AE in-
cluded hyponatremia (n = 1). Possibly related serious AEs in-
cluded grade 2 sinus bradycardia in one patient, grade 2 hematuria,
and grade 1 pericardial effusion in one patient. Overall five (21%)
patients discontinued study participation due to an adverse event.
The ability to conclusively associate siRNA plasma concentration
data with adverse events in this study was limited. Four patients
experienced DLTs in cycle 1; the plasma concentrations observed
in these patients were in the same range as others who did not
Fig. 1. Schematic of nanoparticle assembly. CALAA-01 is manufactured as
two vials. Vial 1 contains the polymer delivery components: a cationic CDP
polyethylene glycol modified with a terminal adamantane group (AD-PEG)
and some AD-PEG conjugated to human transferrin. Vial 2 contains siRNA
designed to reduce the expression of the M2 subunit of ribonucleotide re-
ductase (RRM2). When the vials are mixed together in the pharmacy, the
components self-assemble into a nanoparticle. Cyro-electron micrografts of
CALAA-01 are shown.
Table 1. Patient demographics
Variable No. of patients
Total study population 24
Phase 1a (3–30 mg/m2) 19
Phase 1b (18–27 mg/m2) 5
Median age (y) 63.5 (range 47–83)
Male/female 19/5
ECOG performance status 0/1 11/12
Prior therapies 21
Investigational drugs 13
Chemotherapy 24
Radiotherapy 12
Tumor types
Melanoma 5
Gastrointestinal 8
Prostate 2
Others* 9
Median no. of cycles/patient 2 (range 1–5)
ECOG, Eastern Cooperative Oncology Group.
*See SI Appendix, Table S3.
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experience DLTs. Furthermore, there was no correlation between
elevated plasma cytokine levels and severity of patient AEs.
Pharmacokinetics of CALAA-01 in Humans and Animals. Human
pharmacokinetic (PK) data are illustrated in Fig. 2. We observed
a rapid decline of the plasma concentrations of the siRNA com-
ponent of CALAA-01 to below the limit of detection by 30 min
after the end of infusion in almost all patients (Fig. 2A). These
findings are consistent with the preclinical data in mice (13), rats,
and monkeys (SI Appendix, Fig. S2A). Plasma siRNA concentra-
tion data after CALAA-01 infusion was obtained in multiple
treatment cycles from seven subjects and appeared to be consis-
tent within subjects across cycles. Fig. 2B shows the plasma siRNA
concentration after four individual doses (across three cycles) of
CALAA-01 in a single patient. The rate of plasma siRNA con-
centration decline after each dose was similar. There was no ap-
parent accumulation of CALAA-01 siRNA upon multiple dosing
in any patient.
Data shown in Fig. 2C demonstrate the relationship between
the dose of CALAA-01 to the plasma siRNA area under the
curve (AUC) and the maximal concentration (Cmax) after i.v.
infusion. AUC and Cmax increased with dose, consistent with the
preclinical data in rats and monkeys. Cmax and AUC appeared to
be linearly related in all species (SI Appendix, Fig. S2B). Fig. 2D
illustrates the Cmax dose scaling of CALAA-01 across four spe-
cies (rat, dog, monkey, and human). These data were best fit
when Cmax was plotted against dose in weight (mg/kg) rather
than dose in body-surface area (mg/m2). Conversion on mg/m2
bases was carried out as proposed by Reagan-Shaw et al. (14).
CALAA-01 Causes Minimal Liver and Kidney Toxicity in Humans. The
primary toxicities observed in preclinical studies with CALAA-01
were liver and kidney toxicities as evidenced by dose-dependent
elevations in liver enzymes, creatinine, and blood urea nitrogen
(BUN) in rats and monkeys (SI Appendix, Figs. S3 and S4). The
polymer delivery components of CALAA-01 (vial 1) when ad-
ministered without siRNA (vial 2) induced similar elevations in
liver enzymes, creatinine, and BUN; however, in monkeys, the
full CALAA-01 formulation (vial 1 + vial 2) trended toward
increased liver and kidney toxicity compared with the polymer
delivery components alone. Postmortem tissue examination of
monkeys and rats treated with CALAA-01 or polymer delivery
components alone revealed similar pathologic changes in liver
(increased monocytes/Kupffer cell hypertrophy) and kidney
(tubular necrosis). These data suggest that the polymer delivery
components of CALAA-01 were primarily responsible for the
liver and kidney toxicity observed. To mitigate the possibility
of kidney toxicity in patients, the treatment protocol included
a pretreatment i.v. hydration bolus of 500 mL of 5% (wt/vol)
dextrose in water before CALAA-01 infusions, and the patients
were encouraged to drink 2–3 L of fluids per day while partici-
pating in the study.
The human serum chemistry data are presented in Fig. 3A.
CALAA-01 treatment resulted in minimal and clinically in-
significant dose elevations in serum aspartate transaminase (AST)
and alanine amino transferase (ALT) (several patients had ele-
vated liver enzymes at pretreatment), and no elevation in BUN or
serum creatinine over pretreatment values was observed. When
followed longitudinally over five cycles of therapy, serum AST and
ALT were noted to increase at the start of each treatment cycle
and return to baseline in the interim whereas serum creatinine
remained stable (Fig. 3B).
CALAA-01 Treatment Resulted in Dose-Dependent Platelet Count
Decreases in Both Animals and Humans. SI Appendix, Figs. S5 and
S6, provide data that summarize the effects of CALAA-01 treat-
ment on monkey and rat coagulation parameters and platelet
count. CALAA-01 treatment in both rats and monkeys resulted in
transient prolongation of activated partial thromboplastin time
(APPT) and a marked drop in platelet count. Fibrinogen levels
were depressed following CALAA-01 treatment in monkeys, but
were elevated following treatment in rats. Prothrombin time (PT)
was unaffected in either species. Treatment with the CALAA-01
polymer delivery components alone induced identical changes in
these coagulation parameters, except for PT in monkeys, which
was elevated following polymer delivery component treatment but
not CALAA-01 treatment. These data suggest that the polymer
delivery components of CALAA-01 were likely responsible for
alterations in coagulation parameters and platelet counts follow-
ing CALAA-01 infusion.
Fig. 4 A and B summarize the effects of CALAA-01 treatment
on human coagulation parameters and platelet count. As in the
preclinical animal models, CALAA-01 treatment resulted in
marked dose-dependent, but clinically insignificant, decline in
platelet counts; however, other coagulation parameters (APPT,
PT, fibrinogen) where unaffected. When followed longitudinally
over four cycles in a single patient (30 mg/m2 doses), platelet
count initially declined over cycles 1 and 2; however, it then
recovered over the subsequent two treatment cycles. No long-
term effects on APPT, PT, or fibrinogen levels were observed in
this patient.
CALAA-01 Treatment Did Not Alter Serum-Complement Function in
Animals and Humans. SI Appendix, Table S8, provides data that
summarizes the effects of CALAA-01 treatment on monkey se-
rum complement activity. Plasma Bb (activated complement
factor B) is a specific and sensitive marker for activation of the
alternative complement pathway, which has been shown to be
most appropriate for use in detecting complement activation
induced by oligonucleotides, as this class of molecules has been
shown to specifically induce alternative pathway activation (15).
No appreciable elevation in serum Bb was observed over base-
line increases (baseline increases result from restraining the
animals for treatment). CH50 reflects total hemolytic comple-
ment capacity and is measured ex vivo; it reflects the residual
capacity of the entire system to form membrane attack com-
plexes when triggered ex vivo, and the occurrence of a comple-
ment activation event in vivo will therefore result in a decrease
in CH50 (i.e., due to consumption of complement factors). A
marked reduction in CH50 for most of the polymer delivery
component-treated monkeys was observed at the end of infusion
with complete or nearly complete recovery by 6 h postinfusion.
There were also reductions in CH50 for several CALAA-01–
treated animals, but there was no clear dose dependence in
terms of the incidence of animals with distinct decreases in CH50
Fig. 2. PK assessment of CALAA-01 in patients and across species. (A) Time
course of average plasma concentration of the siRNA component of CALAA-
01 following the end of infusion for all dosing cohorts. (B) Time course of
plasma CALAA-01 siRNA following the end of infusion from cycles 1–3 of
CALAA-01 from one patient who received 30 mg/m2 CALAA-01. Plasma
concentration curves are similar at each cycle. Lines connecting data points
are guides for the eye only. (C ) AUC and Cmax relationship to dose in
humans. (D) Scaling of CALAA-01 Cmax across four different species.
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or the group mean values. These data suggest that the polymer
delivery components’ ability to activate complement is mitigated
when formulated as the CALAA-01 nanoparticle, consistent with
previously published in vitro complement activation studies (10).
Fig. 4C shows data that summarize the effect of CALAA-01
treatment on human complement activity. No appreciable cha-
nge in level of Bb split product or CH50 activity was observed
following CALAA-01 dosing in humans. Of note, a single patient
in the 24-mg/m2 dose cohort had CH50 pretreatment values at
near 0 and had a large relative drop in CH50 after the day 22
dose; however, the absolute change was minimal.
Effects of CALAA-01 Treatment on Other Hematologic Parameters in
Animals and Humans. SI Appendix, Figs. S7 and S8, provides data
that summarize the effects of CALAA-01 treatment on monkey
and rat hematologic parameters. In both species, dose-dependent
decreases in serum hemoglobin and red blood cell count were
observed following CALAA-01 treatment. These effects were
similar in groups dosed with the polymer delivery components
alone. In monkeys, treatment with both CALAA-01 and polymer
delivery components alone resulted in reduced reticulocyte counts
(a measure of new red blood cell production). These data suggest
that, in monkeys, the polymer delivery components of CALAA-01
interfere with new red blood cell production, thereby preventing
replenishment of the red cells lost following the repeated phle-
botomy necessary to obtain the serum toxicology specimens. Dose-
dependent white blood cell count elevations were also observed in
monkeys and rats treated with either CALAA-01 or polymer de-
livery components alone.
SI Appendix, Fig. S9, shows data that summarizes the effects
of CALAA-01 treatment on human hematologic parameters.
No dose-dependent effects on serum hemoglobin, red blood cell
count, or lymphocyte counts were observed. A single patient
receiving 24 mg/m2 of CALAA-01 was found to have severe ane-
mia that was possibly related to CALAA-01 treatment. Two
subjects in the phase Ib cohort were found to have lymphopenia
that was deemed probably treatment related.
Mild, Dose-Dependent Elevations in Serum Cytokines Following
CALAA-01 Treatment Were Observed in Animals and Humans. The
siRNA component of CALAA-01 is not chemically modified. Much
preclinical work has demonstrated that nonchemically modified
siRNAs can be immunostimulatory under certain conditions (16).
Specifically, systemic administration of siRNA with lipid carriers
can cause significant immunostimulation. However, when adminis-
tered intravenously alone, nonchemically modified siRNAs do not
necessarily result in immunostimulation in mice (17). Additionally,
other cationic polymer-based siRNA/nanoparticle systems have
been shown to not elicit a pronounced immune response in vivo
(18). Preclinical data characterizing the immune response to
CALAA-01 dosing in monkeys has previously been reported
(19). Elevated levels of IL-6 were observed at the highest dosing
group (27 mg/kg). Increasing amounts of IL-12 and IFN-γ were
observed in one monkey at 9 and 27 mg/kg, respectively. How-
ever, the increases in these cytokines were not quantitatively
impressive or suggestive of intensive immunostimulation.
Fig. 5A shows data that summarize the assessment of CALAA-01
treatment-induced immune responses in humans. Plasma and
serum were obtained from study patients at prescribed time points
and analyzed for cytokines (IL-2, IL-4, IL-6, IL-10, IL-12p40,
IL-12p70, TNF-α, and IFN-γ). These results indicate apparent
treatment-related elevations in some cytokines—namely IL-6,
IL-10, TNF-α, and IFN-γ. No other cytokines showed any ap-
parent trends or changes in response to CALAA-01 administra-
tion. These elevations were all transient in nature, with cytokine
levels returning to baseline by 24 h after the end of infusion in all
cases (SI Appendix, Fig. S10). Fig. 5B shows the serum IL-6, IL-10,
TNF-α, and IFN-γ levels post dose over six cycles of treatment in
Fig. 3. Minimal evidence for liver or kidney toxicity of CALAA-01 in
humans. (A) Human serum liver enzymes and kidney markers plotted against
dose level. Data are from various cycle dates 24 h post CALAA-01 infusion.
Pretreatment values are presented to the right of the dotted lines. (B) Liver
enzymes and kidney markers over 98 d in a patient that received six cycles of
CALAA-01 at 30 mg/m2. Lines connecting data points are guides for the eye
only. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN,
blood urea nitrogen.
Fig. 4. Effects of CALAA-01 on human coagulation and complement. (A)
Coagulation values plotted against dose level of CALAA-01. Data are from
various cycle dates 6 h post CALAA-01 infusion for PT and APPT and 24 h post
infusion for platelets and fibrinogen. Pretreatment values are presented to
the right of the dotted lines. (B) Coagulation values over 65 d in a patient
that received four cycles of CALAA-01 at 30 mg/m2. Lines connecting data
points are guides for the eye. (C) Complement levels plotted against dose
level of CALAA-01. APPT, activated partial thromboplastin time; CH50, total
hemolytic complement capacity in serum; PT, prothrombin time.
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a single patient (30 mg/m2 doses). IL-6 response attenuated with
each dose whereas IL-10 response increased upon continued
dosing. IL-6 and TNF-α are each indicative of an inflammatory
response; the fact that both were transiently elevated in some
patients suggests that CALAA-01 induces an inflammatory re-
sponse in some patients at some of the higher dose levels. IL-10
is indicative of a T helper 2 (Th2)-mediated immune response;
however, IL-4 is indicative of the same type of response, and
CALAA-01–dependent changes in IL-4 levels were not observed.
Overall, the results suggest that CALAA-01 may induce a Th2-
mediated immune response in some subjects at some of the higher
dose levels examined in the clinical study.
Discussion
PK Correlations Between Animal Models and Patients. A question in
the emerging field of nanoparticle-based therapeutics is how doses
should be scaled from preclinical animal models to patients.
Should scaling be based on body weight or on body-surface area?
Studies with liposome nanoparticles suggest that allometric scaling
based on body weight works reasonably well (20). However, the
AUC of a polymer-based nanoparticle of camptothecin (CRLX101)
scaled best across species based on body-surface area (21). Here,
we find that allometric scaling across species best correlates
with body weight rather than with body-surface area. Scaling of
CALAA-01 is based on Cmax rather than AUC. We chose Cmax
for correlation because the rapid elimination of CALAA-01
resulted in too few data points for accurate AUC calculation
(however, Cmax and AUC were found to be linearly related).
The clearance mechanism of CALAA-01 is different from
other nanoparticle-based therapeutics. The monocyte phagocytic
system is thought to be primarily responsible for nanoparticle
clearance (20). However, CALAA-01 is cleared mainly through
the kidney due to its interaction with the renal filtration barrier
(13). Therefore, PK observations of CALAA-01 may be gener-
alizable only to other nanoparticles that are held together by
electrostatic interactions between the carrier molecules (posi-
tively charged) and the siRNA (negatively charged).
Toxicity Correlations Between Preclinical Models and Clinical Results.
Based on the preclinical animal data, the major concerns for
CALAA-01 in the clinic were kidney and liver toxicity. Surpris-
ingly, no changes in serum creatinine or BUN were observed in
patients treated with CALAA-01. It is possible that the pre-
infusion IV hydration protocol was sufficient to mitigate this
toxicity. Alternatively, it is possible that humans are less sus-
ceptible to the polymer delivery component-induced kidney
toxicity or that CALAA-01 dose levels were below those required
to induce kidney injury in humans. There was no evidence of
overt liver toxicity in the clinic. However, in some patients there
did appear to be a slight and clinically insignificant rise in serum
liver enzyme at the start of each cycle. Regardless, neither of
these two major toxicity concerns resulted in AEs in the clinic.
Other toxicity concerns from the preclinical animal data included
decreases in platelet counts, reticulocyte count, and increased
APPT (primarily in monkeys). In patients, dose-dependent, but
clinically insignificant, decreases in platelet counts were observed.
Anemia was observed in two patients; however, there was no dose
dependence. Additionally, no effects on coagulation values (APPT,
PT, or fibrinogen level) were observed in patients. These effects
correlated well with those observed in animals, except for the
effects on APPT (marked in monkeys, but not in rats).
Understanding Preclinical and Clinical Toxicity Profiles. We can
conclude from the preclinical toxicity studies that one or more
of the delivery components within CALAA-01, rather than the
siRNA component (active pharmaceutical ingredient), were
primarily responsible for the adverse effects observed. In al-
most every parameter measured, administration of the polymer
delivery components alone to animals resulted in similar results
as with CALAA-01 administration (e.g., liver/kidney tox, platelet
drop, APPT rise). To demonstrate the biologic feasibility of
liver and kidney toxicity of polymer components, we examined
the biodistribution of a fluorescently labeled formulation of
the CALAA-01 excipients in mice (SI Appendix, Fig. S11). Bright
fluorescence signal was observed throughout the kidney (localized
primarily to glomeruli and tubule lumens) and liver sinusoids.
Weak fluorescence signal was detected in several other organs as
well. These data lead us to speculate that purification of any free
polymer delivery component material remaining after CALAA-01
assembly in the formulation may provide a reduced toxicity profile
and should be investigated.
It should be noted that in monkeys, but not in rats, fully for-
mulated CALAA-01 trended toward increased liver and kidney
toxicity compared with equivalent amounts of free polymer de-
livery components alone. We speculate that this increased tox-
icity resulted from the conglomeration of the polymer delivery
components in a nanoparticle formulation rather than from any
effect of the siRNA.
The majority of AEs resulting from CALAA-01 in humans were
primarily hypersensitivity and sequelae of acute immune responses
(flushing, fever, fatigue, etc.). Here, too, we suspect that the de-
livery components of CALAA-01 were the culprit. In both rats and
dogs, CALAA-01 administration resulted in hypersensitivity reac-
tions (flushing, skin edema, increased respiratory rates). SI Appendix,
Table S9, shows histamine release following CALAA-01 treatment
in male beagle dogs. The delivery components alone resulted in
a 10-fold higher histamine release than CALAA-01. Uchida et al.
have shown how cationic polymers can induce histamine release in
rat mast cells (22). The histamine release following CALAA-01 was
mitigated by standard pretreatment with antihistamines and ste-
roids. All patients in the study received a similar pretreatment
before CALAA-01 administration.
The potential mechanisms for the observed DLTs are less
clear. Although the dose-limiting fatigue experience by one pa-
tient was consistent with the milder fatigue observed during dose
escalation in other patients, the other DLTs (ischemic colitis,
lymphopenia, severe hypersensitivity reaction, and hypona-
tremia) were not expected based on dose level or preclinical
toxicity data. Furthermore, two of the patients who experienced
Fig. 5. CALAA-01 treatment resulted in mild dose-dependent immunosti-
mulation. (A) Various cytokine levels, expressed as ratio over baseline,
plotted against CALAA-01 dosing level. (B) Cytokine levels over six cycles of
CALAA-01 treatment at 30 mg/m2 in a single patient. Data from each cycle
were collected immediately before CALAA-01 infusion and 2, 6, and 24 h
post infusion. The x axis is labeled as cycle number (C#), overall time since
treatment initiation (D#), and hours post infusion as appropriate.
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DLTs were in the phase Ib cohort and received only doses of
18 mg/m2 CALAA-01. During dose escalation in phase Ia, this
dose was very well tolerated by all patients. However, three of the
four patients to receive only this dosage of CALAA-01 during
phase Ib experienced grade 3 toxicities, including two DLTs.
It is possible that these toxicities were simply not observed
during dose escalation in phase Ia due to the potentially sto-
chastic nature of these AEs. In SI Appendix, Table S1, we illus-
trate the date of first dose of cycle 1 for every patient in the
study compared with the AEs that they experienced. The ∼1-y
enrollment gap is represented by the thick black line in SI Appendix,
Table S1. Despite the treatment dose trend after this gap essentially
being a dose de-escalation phase (30 to 24 to 18 mg/m2) starting in
July 2010, there was a notable trend in increases in the number
of higher severity and acute toxic events despite the general dose
reduction over this time. Thus, an alternative explanation of this
AE trend is the possibility that an aspect of CALAA-01 changed
because it was manufactured at the beginning of the trial (only
a single batch was manufactured for this trial). Delivery com-
ponents from a different (nonclinical) batch of CDP, AD-PEG,
and siRNA components stored and analyzed at the M.E.D.
laboratory (California Institute of Technology) have shown ex-
cellent stability for times longer than the phase Ia/b clinical trial.
However, Tf-PEG-Ad conjugates have shown structural alter-
ations. Thus, if there were any aspect of the clinical CALAA-01
formulation that did change over this time period, we speculate
that the transferrin-targeting agent is the most likely component
of CALAA-01 to have done so (possibly mis-folded, aggregated,
or degraded) in a manner not captured via analytics that were
used (more sophisticated analytic methods were used by the M.E.D.
laboratory), thereby resulting in the more severe AEs being ob-
served during the late phase Ia and Ib trials. Admittedly, these post
hoc analyses are speculative because we were not able to analyze
the clinical materials by the analytical methods (used at the
California Institute of Technology) at their time of use; however, we
believe that quality control assays designed to test for these possi-
bilities would be appropriate for any future protein-targeted
nanotherapeutics.
Summary. Taken in total, the evidence provided from animal
studies for CALAA-01 do appear to accurately assess the be-
havior observed in the clinic. Because the DLTs in animals were
in the kidney, a prehydration protocol was used in the clinic to
protect the kidneys, and the DLTs observed in animals were not
observed in humans. CALAA-01 was well tolerated during the
initial dose escalation portion of the phase Ia study. The delivery
system used in CALAA-01 does provide for targeted delivery of
functional siRNA (2). However, the full potential of CALAA-01
was not evaluated in this phase Ia/Ib clinical study.
Materials and Methods
Complete details of materials and methods are provided in SI Appendix.
Patient Enrollment. Twenty-four patients were enrolled in the study. Eligible
patients were at least 18 y of agewith histologically or cytologically confirmed
solid malignancy that is metastatic or unresectable, refractory to standard
therapy, or for which no standard curative or palliative therapy is available.
The additional eligibility criteria included were Eastern Cooperative Oncology
Group (ECOG) performance status ≤1; life expectancy of at least 6 mo; ade-
quate marrow, hepatic. and renal function as well as acceptable hemato-
logical and biochemical values. All eligible patients had recurring tumors or
tumors that radiation therapy has failed. Patients who received prior adju-
vant, neoadjuvant, or any other therapy for metastatic disease needed to
be fully recovered from prior diagnostic or therapeutic surgery for at least
30 d before initial dosing. No restriction was placed on the number of cycles
or regimens of prior therapy. Patients who were allergic to Benadryl
(Diphenhydramine; McNEIL-PPC Inc.), Zantac (Ranitidine; Boehringer Ingelheim),
Zofran (Ondansetron; GlaxoSmithKline), dexamethasone, other drugs in these
classes or contrast media required for protocol testing were not eligible.
The study was approved by the institutional review board or ethics
committee at each participating center (South Texas Accelerated Research
Therapeutics, San Antonio, TX; University of California, Los Angeles Jonsson
Comprehensive Cancer Center, Los Angeles, CA; and City of Hope Compre-
hensive Cancer Center, Duarte, CA) and was performed in accordance with
the Declaration of Helsinki and Good Clinical Practice Guidelines. Written
informed consent was obtained from all patients before study entry.
Plasma siRNA Concentration, Complement Factors, and Cytokine Measurements.
Plasma concentrations of the siRNA were determined by using a modified
hybridization-ligation assay (23). Plasma Bb levels were determined by ELISA.
Serum CH50 values were determined by a standard sheep erythryocyte lysis-
based assay. Serum cytokines levels were determined by using commercially
available kits: for IL-6 and IL-12, ELISA; and for IFN-γ, IL-10, IL-4, and TNF-α,
multiplex kits and a Luminex instrument (Invitrogen).
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